Bayer's Phase II Study: Anti-alpha2 Antibody for Deep Vein Thrombosis

Bayer announced the initiation of a Phase 2 clinical trial (SIRIUS study) for BAY3018250, the first anti-alpha2 antiplasmin (anti-a2ap) antibody in patients with deep vein thrombosis (DVT). 

The results of this study provide evidence for the potential of anti-a2ap antibodies as a therapeutic option for serious diseases. "We are pleased to be able to advance our anti-a2ap antibody to the next phase of clinical development in patients with deep vein thrombosis," said Christian Rommel, Member of the Committee, Management and CEO of the Pharmaceutical Division of Bayer AG.

Research and development. "This study will also help to better understand whether anti-a2ap antibodies are effective as a thrombolytic drug to treat patients with a medical condition. By targeting alpha2 antiplasmin, we will be more precise in modifying plasmin to break down thrombotic clots.

The continued success of the first human clinical trial, the objective of this randomized, double-masked, placebo-controlled, multicenter phase 2 study (SIRIUS study), evaluated the efficacy and safety of BAY3018250 in patients with symptomatic deep vein thrombosis. BAY3018250 is designed to target antiplasmin alpha2. The main function of a2ap is to balance the formation and lysis of blood clots by inhibiting the enzymatic activity of plasmin.

Bayer is a leader in cardiovascular disease, advancing innovative treatments for cardiovascular (CVD) disease and unmet medical needs. This strategy will unlock the future potential of the cardiovascular market by transforming Bayer's portfolio into the heart of excellence, addressing the high burden of cardiovascular disease and driving long-term growth. Bayer's cardiovascular disease portfolio includes many new products and compounds in various preclinical and clinical development stages.

Bayer is a global company with core life sciences, health, and nutrition competencies. Our products and services are designed to help people and the world survive, supporting efforts to address the major challenges of a growing and aging global population.